Top

Published in:

Open Access 01-08-2024 | Breast Cancer | Research

Cardiac safety of ribociclib evaluated with 24-hour rhythm Holter electrocardiogram

Authors: Ayse Irem Yasin, Mahmut Uluganyan, Zehra Sucuoglu Isleyen, Atakan Topcu, Abdallah Tm Shbair, Melih Simsek, Mehmet Besiroglu, Yeliz Emine Ersoy, Hacı Mehmet Türk, Mesut Seker

Published in: Supportive Care in Cancer | Issue 8/2024

Abstract

Objective

We aimed to evaluate cardiac safety profile of ribociclib with 24-h rhythm Holter ECG.

Material and method

Forty-two female metastatic breast cancer patients were included in the study. Rhythm Holter ECG was performed before starting treatment with ribociclib and after 3 months of the treatment initiation.

Results

The mean age of the patients was 56.36 ± 12.73. 52.4% (n = 22) of the patients were using ribociclib in combination with fulvestrant and 47.6% (n = 20) with aromatase inhibitors. None of the patients developed cardiotoxicity. When the rhythm Holter results before and in third month of the treatment were compared, there was no statistically significant difference.

Conclusion

This is the first study evaluating effects of ribociclib treatment on cardiac rhythm with Holter ECG. The findings suggested ribociclib has a low risk of causing early cardiotoxicity.

Harbeck N, Penault-Llorca F, Cortes J et al (2019) Breast cancer. Nat Rev Dis Prim 5(1):66CrossRefPubMed

Jerzak KJ, Bouganim N, Brezden-Masley C et al (2023) HR+/HER2-advanced breast cancer treatment in the first-line setting: Expert Review. Curr Oncol 30(6):5425–5447CrossRefPubMedPubMedCentral

Cardoso F, Paluch-Shimon S, Senkus E et al (2020) 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol 31(12):1623–1649CrossRefPubMed

Johnston S, Martin M, Di Leo A et al (2019) MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer 5:5CrossRefPubMedPubMedCentral

Hortobagyi GN, Stemmer SM, Burris HA et al (2018) Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol 29(7):1541–1547CrossRefPubMed

Tripathy D, Im SA, Colleoni M et al (2018) Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol 19(7):904–915CrossRefPubMed

Finn RS, Martin M, Rugo HS et al (2016) Palbociclib and letrozole in advanced breast cancer. N Engl J Med 375(20):1925–1936CrossRefPubMed

Hortobagyi GN, Stemmer SM, Burris HA et al (2022) Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med 386(10):942–950CrossRefPubMed

Slamon DJ, Fasching PA, Hurvitz S et al (2023) Rationale and trial design of NATALEE: a phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2- early breast cancer. Ther Adv Med Oncol 15:17588359231178124CrossRefPubMedPubMedCentral

10.

Ball S, Swarup S, Sultan A, Thein KZ (2021) Increased risk of cardiac conduction abnormalities with ribociclib in patients with metastatic breast cancer: a combined analysis of phase III randomized controlled trials. Hematol Oncol Stem Cell Ther 14(3):260–262CrossRefPubMed

11.

Santoni M, Occhipinti G, Romagnoli E et al (2019) Different cardiotoxicity of palbociclib and ribociclib in breast cancer: gene expression and pharmacological data analyses, biological basis, and therapeutic implications. BioDrugs 33(6):613–620CrossRefPubMed

12.

Coppola C, Rienzo A, Piscopo G, Barbieri A, Arra C, Maurea N (2018) Management of QT prolongation induced by anti-cancer drugs: target therapy and old agents. Different algorithms for different drugs. Cancer Treat Rev 63:135–143CrossRefPubMed

13.

Fradley MG, Nguyen NHK, Madnick D et al (2023) Adverse cardiovascular events associated with cyclin-dependent kinase 4/6 inhibitors in patients with metastatic breast cancer. J Am Heart Assoc 12(12):e029361CrossRefPubMedPubMedCentral

14.

Richardson DR, Parish PC, Tan X et al (2022) Association of QTc formula with the clinical management of patients with cancer. JAMA Oncol 8(11):1616–1623CrossRefPubMedPubMedCentral

15.

Hortobagyi GN, Stemmer SM, Burris HA et al (2016) Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med 375(18):1738–1748CrossRefPubMed

16.

Sledge GW Jr, Toi M, Neven P et al (2020) The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial. JAMA Oncol 6(1):116–124CrossRefPubMed

17.

Harbeck N, Rastogi P, Martin M et al (2021) Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. Ann Oncol 32(12):1571–1581CrossRefPubMed

18.

Durairaj C, Ruiz-Garcia A, Gauthier ER et al (2018) Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer. Anticancer Drugs 29(3):271–280. https://doi.org/10.1097/CAD.0000000000000589CrossRefPubMedPubMedCentral

19.

Chappell JC, Chiang AY, Royalty J, Coleman H, Kulanthaivel P, Turner PK (2023) Abemaciclib does not increase the corrected QT interval in healthy participants. Clin Transl Sci 16(9):1617–1627. https://doi.org/10.1111/cts.13573CrossRefPubMedPubMedCentral

20.

Slamon DJ, Neven P, Chia S et al (2018) Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol 36(24):2465–2472CrossRefPubMed

21.

Parati MC, Pedersini R, Perego G et al (2022) Ribociclib in the treatment of hormone-receptor positive/HER2-negative advanced and early breast cancer: overview of clinical data and patients selection. Breast Cancer (Dove Med Press) 14:101–111PubMed

Title: Cardiac safety of ribociclib evaluated with 24-hour rhythm Holter electrocardiogram
Authors: Ayse Irem Yasin
Mahmut Uluganyan
Zehra Sucuoglu Isleyen
Atakan Topcu
Abdallah Tm Shbair
Melih Simsek
Mehmet Besiroglu
Yeliz Emine Ersoy
Hacı Mehmet Türk
Mesut Seker
Publication date: 01-08-2024
Publisher: Springer Berlin Heidelberg
Keywords: Breast Cancer
Breast Cancer
Fulvestrant
Published in: Supportive Care in Cancer / Issue 8/2024
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-024-08702-0

Effect of exercise on fatigue and depression in breastcancer women undergoing chemotherapy: a systematic review and meta-analysis

Fatigue
Review

Exploring the integration of dentistry within a multidisciplinary palliative care team: does bedside dental care improve quality of life and symptom burden in inpatient palliative care patients?

Open Access
Denture
Research

Optimal hyperglycemia thresholds in patients undergoing chemotherapy: a cross sectional study of oncologists’ practices

Open Access
Hyperglycemia
Research

Communication patterns in families affected by parental cancer from the healthy parents’ perspective—process evaluation of the complex intervention Family-SCOUT

Open Access
Research

Adopting a systems-thinking approach to optimise dietary and exercise referral practices for cancer survivors

Open Access
Research

Patient attitudes and experiences towards exercise during oncological treatment. A qualitative systematic review

Open Access
Review

Women’s health knowledge hub

Menopause
Clinical Collection

Elevate your patient care with our comprehensive, evidence-based medical education on women's health. Designed to help you provide exceptional care for your female patients at every stage of life, we provide expert insights into topics such as reproductive health, menopause, breast cancer and sex-specific health risks and precision medicine.

Genetic Testing
On-demand webinar

In this interactive webinar, experts Dr. Subbiah, Dr. Drilon, and Dr. Williams discuss best pathological practices within NSCLC and thyroid cancer, as well as how genomic testing can improve outcomes in clinical practice, using patient case studies as illustrations.

This content is intended only for US-based healthcare providers.

Supported by:

Illumina, Inc., and Eli Lilly and Company

Dr. Vivek Subbiah

Dr. Alexander Drilon

Dr. Michelle Williams

Developed by: Springer Healthcare

Watch now

Elevate your expertise in aplastic anemia (Link opens in a new window)

Aplastic Anemia
Independent Medical Education

Transform the way you care for your patients with aplastic anemia with our 3-module series using real-world case studies and expert insights. Discover why early diagnosis matters, explore the benefits and risks of current treatments, and develop tailored approaches for complex cases.

Supported by:

Pfizer

Developed by: Springer Healthcare IME

Learn more

Keynote series | Spotlight on managing health in obesity

Springer Medicine

Cardiac safety of ribociclib evaluated with 24-hour rhythm Holter electrocardiogram